Raloxifene
Evista. Second-generation SERM. Preferred over Tamoxifen for gynecomastia treatment and reversal due to stronger breast tissue selectivity.
Overview
Evista. Second-generation SERM. Preferred over Tamoxifen for gynecomastia treatment and reversal due to stronger breast tissue selectivity.
Blocks estrogen at breast tissue (more effective for existing gyno than Tamoxifen), weaker LH/FSH stimulation than Tamoxifen (less useful for PCT), beneficial for lipids, positive effect on bone density, does not raise SHBG as significantly as Tamoxifen
Compound Guide
Mechanism: Selective Estrogen Receptor Modulator. Acts as estrogen antagonist at breast tissue and bone, neutral/agonist at uterus (unlike Tamoxifen). Strongest SERM for breast tissue estrogen blockade.
Dosage:
- Gyno prevention (on cycle): 30mg/day
- Active gyno treatment / reversal: 60mg/day for 3-6 months
- Acute gyno flare: 60mg/day + Letrozole 2.5mg/day for 7-10 days, then Raloxifene 60mg/day alone
Administration:
- Oral tablet, once daily, with or without food
- Long treatment duration for gyno reversal — 3-6 months minimum
Key Notes:
- Gold standard for gyno reversal in bodybuilding — more tissue-selective than Tamoxifen
- Does NOT significantly stimulate LH/FSH — not useful as a primary PCT drug
- Can be run alongside Tamoxifen or Enclomiphene during PCT if gyno is a concern
- Studies show ~80% improvement in gynecomastia with 3-6 months of use at 60mg/day
- Beneficial for lipids — lowers LDL, raises HDL
- Well tolerated long-term — fewer side effects than Tamoxifen
- Monitor: lipids (generally improve), E2 (remains unchanged — Raloxifene blocks at the receptor, does not lower serum E2)
Usage History
Frequently Asked Questions
Quick Reference
Category
SERM
Half-Life
28 hours
Detection Time
N/A